You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: 8,460,381


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,460,381
Title:Methods and devices for the treatment of intervertebral discs disorders
Abstract: Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, are specifically configured with an inert outer layer and an inner layer containing at least one chemonucleolysis agent so as to provide a delayed and controlled release of the chemonucleolysis agent from the inner layer into the disc. The implant can be an elongated solid body having a tapered or rounded insertion end having at least one therapeutic agent in the inner layer of the implant surrounded by an outer layer of inert material.
Inventor(s): Lee; Elaine (Santa Clara, CA)
Assignee: Warsaw Orthopedic, Inc. (Warsaw, IN)
Application Number:13/076,645
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 8,460,381

Introduction

United States Patent 8,460,381, titled "Method and Apparatus for Integrating Manual Input," is a significant patent that has been extensively cited and has had a profound impact on the field of Human-Computer Interaction (HCI). This analysis will delve into the claims of the patent, its significance, and the broader patent landscape it operates within.

Background of the Patent

The patent, issued to Apple Inc., focuses on methods and apparatuses for integrating manual input, particularly in the context of multi-touch interfaces. This technology has been pivotal in the development of modern touch-sensitive devices, such as smartphones and tablets[1].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the method and apparatus for integrating manual input, including the use of multi-touch gestures and the recognition of various touch inputs.

Dependent Claims

Dependent claims further specify the invention by adding additional limitations to the independent claims. These claims often detail specific aspects of the multi-touch interface, such as the detection of pinch-to-zoom gestures or the differentiation between single and multi-touch inputs.

Claim Construction

The construction of these claims is crucial for determining the patent's scope and validity. Recent updates in patent guidance, such as the 2024 USPTO guidance on AI patents, emphasize the importance of evaluating whether claims integrate judicial exceptions into practical applications. This ensures that the claimed invention offers concrete technological improvements[2].

Significance and Impact

Industry Impact

The patent has been highly influential in the tech industry, with numerous citations in subsequent patents. For instance, it is cited by other patents related to touch-sensitive input devices, indicating its role in shaping the development of modern user interfaces[1].

Citation Analysis

Citation analysis reveals that this patent is part of a larger network of HCI research that has been extensively cited by patents. Studies have shown that HCI research papers, including those related to multi-touch interfaces, are cited by patents at a higher rate than papers from other scientific fields[1].

Patent Landscape

Prior Art and Novelty

To assess the strength and potential enforceability of the patent, it is essential to conduct a prior art search. This involves identifying existing technologies or innovations that may affect the validity or patentability of the invention. Effective patent analysis can help identify relevant prior art, ensuring the novelty and non-obviousness of the patent[5].

Freedom to Operate (FTO) Analysis

FTO analysis is critical to ensure that the product or process described in the patent does not infringe on existing patents. This analysis helps businesses avoid legal disputes and costly patent infringement litigation by verifying that they have the right to manufacture, use, or sell their products without violating someone else's intellectual property rights[5].

Competitive Intelligence

Analyzing the patent portfolios of competitors, such as other tech giants, can provide insights into their R&D strategies and technological advancements. This competitive intelligence can help Apple and other companies assess the strength of their competitors and develop strategies to protect and expand their market share[5].

Recent Developments and Legal Framework

USPTO Guidance on AI Patents

The 2024 USPTO guidance update on AI patents provides clarifications on the patent eligibility of AI-related inventions. This guidance is relevant even though the patent in question is not specifically AI-related, as it sets a precedent for evaluating the practical application of technological improvements. The update emphasizes the integration of judicial exceptions into practical applications and the role of AI as a tool in invention development[2].

Design Patent Obviousness

The recent Federal Circuit decision eliminating "improperly rigid" tests for design patent obviousness could have implications for the broader patent landscape. While this decision primarily affects design patents, it underscores the evolving nature of patent law and the need for flexible and nuanced approaches to determining obviousness[4].

Technological Trends and Innovation Insights

Multi-Touch Technology

The patent's focus on multi-touch technology reflects a significant trend in HCI research. Studies have shown that HCI papers related to multi-touch interfaces are highly cited by patents, indicating their importance in driving innovation in user interface design[1].

Artificial Intelligence in Patents

Although the patent does not specifically involve AI, the integration of AI in patent analysis and the development of AI-related inventions is becoming increasingly important. The Artificial Intelligence Patent Dataset (AIPD 2023) by the USPTO highlights the growing role of AI in patent landscapes, providing tools for identifying and analyzing AI-related patents[3].

Key Takeaways

  • Significant Impact: The patent has had a profound impact on the development of touch-sensitive devices and user interfaces.
  • High Citation Rate: It is highly cited by subsequent patents, reflecting its influence on HCI research and industry.
  • Legal and Regulatory Compliance: Ensuring FTO and conducting thorough prior art searches are crucial for the patent's validity and enforceability.
  • Competitive Intelligence: Analyzing competitors' patent portfolios is essential for R&D strategies and market positioning.
  • Evolving Legal Framework: Recent updates in patent law, such as the USPTO guidance on AI patents and the Federal Circuit decision on design patent obviousness, highlight the dynamic nature of patent law.

FAQs

  1. What is the main focus of United States Patent 8,460,381?

    • The patent focuses on methods and apparatuses for integrating manual input, particularly in the context of multi-touch interfaces.
  2. How significant is the citation rate of this patent?

    • The patent is highly cited, with over 4,000 citations, indicating its substantial influence on the development of touch-sensitive devices and user interfaces.
  3. What is the importance of Freedom to Operate (FTO) analysis for this patent?

    • FTO analysis ensures that the product or process described in the patent does not infringe on existing patents, avoiding legal disputes and costly litigation.
  4. How does the 2024 USPTO guidance on AI patents affect the evaluation of this patent?

    • While the patent is not AI-related, the guidance sets a precedent for evaluating the practical application of technological improvements, which can be applied broadly to other patents.
  5. What role does competitive intelligence play in the context of this patent?

    • Analyzing competitors' patent portfolios helps companies assess their strengths and weaknesses, develop strategies to protect and expand market share, and stay competitive in the industry.

Sources

  1. Hancheng Cao, Yujie Lu, Yuting Deng, et al. "A Large-scale Analysis of Patent Citations to HCI Research" CHI ’23, April 23–28, 2023, Hamburg, Germany.
  2. Mintz. "Understanding the 2024 USPTO Guidance Update on AI Patent."
  3. USPTO. "Artificial Intelligence Patent Dataset (AIPD 2023)."
  4. Ballard Spahr. "Full Federal Circuit Eliminates ‘Improperly Rigid’ Tests for Design Patent Obviousness."
  5. Evalueserve. "Patent Analysis."

More… ↓

⤷  Subscribe

Details for Patent 8,460,381

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Discure Medical, Llc CHYMODIACTIN chymopapain For Injection 018663 November 10, 1982 8,460,381 2039-02-26
Discure Medical, Llc CHYMODIACTIN chymopapain For Injection 018663 August 21, 1984 8,460,381 2039-02-26
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 8,460,381 2039-02-26
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 8,460,381 2039-02-26
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 8,460,381 2039-02-26
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 8,460,381 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.